摘要
目的探讨安罗替尼联合替吉奥在晚期肺鳞癌三线治疗中的临床价值。方法选取江西省萍乡市萍矿总医院2018年9月~2019年9月诊断为肺鳞癌Ⅳ期,且经过二线治疗进展的60例患者,按照随机数字表法分为治疗组、对照1组与对照2组,每组各20例。其中治疗组采取安罗替尼+替吉奥治疗,对照1组采取安罗替尼+安慰剂治疗,对照2组采取替吉奥+安慰剂治疗。比较三组的治疗效果与不良反应发生情况。结果三组无进展生存期(PFS)比较,治疗组明显长于对照1组及2组,差异有统计学意义(P<0.05);三组客观缓解率(ORR)比较,差异无统计学意义(P>0.05);三组疾病控制率(DCR)比较,治疗组高于对照1组与对照2组,且总生存期(OS)长于对照1组与对照2组,差异有统计学意义(P<0.05);三组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论安罗替尼联合替吉奥可有效控制患者病情发展,延长患者生存时间,且未增加严重不良反应,值得推广。
Objective To investigate the clinical value of Anlotinib combined with S-1 in the treatment of advanced lung squamous cell carcinoma.Methods A total of 60 patients who were diagnosed with lung squamous cell carcinoma stageⅣand had progressed through second-line treatment were selected in Pingkuang General Hospital,Pingxiang City,Jiangxi Province from September 2018 to September 2019.They were divided into treatment group,control group 1 and control group 2 according to the random number table method,20 cases in each group.The treatment group was treated with Anlotinib+Tiggio,the control group 1 was treated with Anlotinib+placebo,and the control group 2 was treated with Tiggio+placebo.The treatment effect and adverse reactions of the three groups were compared.Results The progression free survival(PFS)of the treatment group was longer than that of the control group 1 and 2,the difference was statistically significant(P<0.05);comparison the objective remission rate(ORR)of the three groups,the difference was not statistically significant(P>0.05).The disease control rate(DCR)of the treatment group was higher than that of the control group 1 and 2,and the overall survival time(OS)was longer than that of the control group 1 and 2,there were significant differences(P<0.05).There was no significant difference in the total incidence of adverse reactions among the three groups(P>0.05).Conclusion The combination of Anlotinib and Tegafur treatment can effectively control the development of patients′condition,prolong the survival time of patients,and does not increase serious adverse reactions,which is worthy of promotion.
作者
花小梅
HUA Xiao-mei(Department of Oncology,Pingxiang Pingkuang General Hospital,Jiangxi Province,Pingxiang337000,China)
出处
《中国当代医药》
2020年第33期53-55,共3页
China Modern Medicine
基金
江西省萍乡市科技计划项目(2018PY095)。
关键词
安罗替尼
替吉奥
晚期肺鳞癌
三线治疗
应用效果
Anlotinib
Tegafur
Advanced lung squamous cell carcinoma
Third line treatment
Application effect